|Bid||18.12 x 1100|
|Ask||18.30 x 800|
|Day's Range||18.12 - 18.97|
|52 Week Range||13.00 - 28.75|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
With no reason to sell off, why wouldn't stocks continue higher on Monday? Let's look at a few top stock trades for Tuesday, when earnings season will begin with the banks. Top Stock Trades for Tomorrow No. 1: Canopy Growth (CGC)Source: Chart courtesy of StockCharts.comThe cannabis space is far from being out of the woods, but there are two names in the group that I have liked recently, one of which is Canopy Growth (NYSE:CGC).Canopy shares are hitting their highest level since October, as shares push higher on Monday. In doing so, CGC is reclaiming both the $22 level and the 100-day moving average.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt might get there in a few days or it might take a few months, but a rally up and over $25 into the upper-$20s shouldn't be out of the question now. * 7 Inflation-Beating REITs to Ground Your Income Portfolio On the downside, it would be best for CGC to hold $21.50 as support. Below that level and bulls will need to see the 50-day and uptrend support (purple line) need to hold as support. Top Stock Trades for Tomorrow No. 2: AT&T (T)Source: Chart courtesy of StockCharts.comResistance continues to hold near $39 for AT&T (NYSE:T), while Monday's pullback is sending T stock right into the 50-day moving average and uptrend support (blue line). This one is simple now.Below uptrend support and the 100-day moving average is in play. Below that and the $36 to $36.50 area is possible. If current support holds, look for a rebound back up to $39. If it can get over that level, AT&T could be looking at $40-plus. Top Stock Trades for Tomorrow No. 3: Roku (ROKU)Source: Chart courtesy of StockCharts.comWhile many growth stocks have been rallying, Roku (NASDAQ:ROKU) has been struggling. Shares did reverse off $127 support on Monday, but still face downtrend resistance (blue line) overhead.Falling below the 20-day and 50-day moving averages does not bode well for momentum, but Roku isn't completely stuck.A move back over downtrend resistance and the 50-day moving average could trigger a rally up to $150-plus. However, a move below $127 puts the $117 to $120 area on watch, with the 200-day moving average just below. Top Stock Trades for Tomorrow No. 4: Aphria (APHA)Source: Chart courtesy of StockCharts.comAt the top, I mentioned that I liked two cannabis stocks. CGC was the first and Aphria (NYSE:APHA) is the other. The latter isn't moving quite as nicely as the former, but it's showing breakout potential.Rallying into the 100-day moving average and downtrend resistance (blue line) now, APHA stock has a chance to power higher and draw in buyers.A move over $5.50 would add to its momentum and put the declining 200-day moving average in play. If it can't hurdle current resistance, see that it holds up over the 50-day moving average. Below that level puts $4.50 back on the table. Top Stock Trades for Tomorrow No. 5: Invitae (NVTA)Source: Chart courtesy of StockCharts.comWhat a wild ride it has been with Invitae (NASDAQ:NVTA). Shares are surging higher on Monday after an update from management on Sunday night regarding 2019 results and 2020 guidance.The news sent shares higher by about 10%, with many longs wondering if this is the start of something big or if it will ultimately deflate like the last pop.The stock is back over $17, while uptrend support (blue line) continues to hold. Shares are clearing downtrend resistance (purple line), and while investors will be looking at $20, that's not the level to watch. Instead, it's the 50-week moving average at $20.55.Over that level and NVTA can really start to find its momentum.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long ROKU, T, APHA and NVTA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Inflation-Beating REITs to Ground Your Income Portfolio * 7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount * 7 Earnings Reports to Watch This Week The post 5 Top Stock Trades for Tuesday: CGC, T, ROKU appeared first on InvestorPlace.
When meeting space is at a premium during the week of biotech's big dealmaking conference, a Union Square tenant creatively bonds with a San Francisco company.
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2019 results, driving strong growth in volume and revenues, signaling continued momentum going into 2020. The company accessioned more than 482,000 samples and generated approximately $216 million in revenue in 2019. The company also announced 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue. Invitae has now provided in-depth medical genetic sequencing for more than one million patients since launch, including more than 750,000 in the past two years.
Life sciences companies like to release a flurry of news in the days ahead of the giant J.P. Morgan Healthcare Conference in San Francisco to create fresh nuggets for potential investors and partners to gnaw on. Yet too much noise sometimes can hurt their message.
Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics joined Behind the Seizure®, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. The program will also be expanded to make no-charge testing available for healthcare providers to order for any child under the age of eight who has an unprovoked seizure.
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 7:30 a.m. Pacific at the Westin St. Francis in San Francisco. Following the company presentation, management will participate in a breakout session at 8:00 a.m. Pacific.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™, an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symptoms of having a skeletal dysplasia, a group of rare, mostly genetic disorders that affect bones and joints and impact growth and development in children.
Genetic testing firms like Natera, Invitae and Fulgent are benefiting from declining costs in whole genome sequencing, a version of DNA exams that could conquer current consumer varieties.
SAN FRANCISCO , Nov. 21, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Shelly Guyer , chief financial officer of Invitae, will participate ...
PHILADELPHIA, Nov. 15, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease. The first study on the platform will evaluate genetics in cardiovascular disease and was announced in conjunction with the American Heart Association's Scientific Sessions where researchers are presenting data on genetic screening in familial hypercholesterolemia.
The two big rounds were a $400 million round for a Chinese Tesla competitor whose U.S. operations are in Mountain View and a $100 million round for San Francisco-based food delivery unicorn DoorDash.
Invitae's third acquisition in four months is indicative of consolidation in the genetic testing arena.
SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.
BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions. "Our overall health and longevity are determined about 30 percent by genetics," said Debra Leonard, MD, PhD, Chair, Pathology and Laboratory Medicine.
Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.
Invitae (NVTA) delivered earnings and revenue surprises of -32.69% and 2.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Increased quarterly revenue by 51% and volume by 65% year-over-year -- -- Now in network with Cigna, all major payers with approximately 295 million covered lives -- -- Hosting conference call and webcast ...
SALT LAKE CITY , Nov. 5, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic ...